Jennifer R. Brown, MD, PhD presents an interim analysis from the ALPINE study of zanubrutinib vs. ibrutinib in patients with R/R CLL/SLL presented at the 2021 European Hematology Association virtual congress.
Jennifer R. Brown, MD, PhD, Dana Farber Cancer Institute
Advertisement
Articles by Jennifer R. Brown, MD, PhD, Dana Farber Cancer Institute
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
5